312 related articles for article (PubMed ID: 11249575)
1. The potential of PDE4 inhibitors in asthma or COPD.
Spina D
Curr Opin Investig Drugs; 2000 Oct; 1(2):204-13. PubMed ID: 11249575
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD).
Barnette MS
Prog Drug Res; 1999; 53():193-229. PubMed ID: 10616299
[TBL] [Abstract][Full Text] [Related]
4. Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
Smith VB; Spina D
Curr Opin Investig Drugs; 2005 Nov; 6(11):1136-41. PubMed ID: 16312135
[TBL] [Abstract][Full Text] [Related]
5. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
Dastidar SG; Rajagopal D; Ray A
Curr Opin Investig Drugs; 2007 May; 8(5):364-72. PubMed ID: 17520865
[TBL] [Abstract][Full Text] [Related]
7. Type 4 phosphodiesterase-dependent pathways: role in inflammatory processes.
Jacob C; Martin-Chouly C; Lagente V
Therapie; 2002; 57(2):163-8. PubMed ID: 12185965
[TBL] [Abstract][Full Text] [Related]
8. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents.
Doherty AM
Curr Opin Chem Biol; 1999 Aug; 3(4):466-73. PubMed ID: 10419856
[TBL] [Abstract][Full Text] [Related]
10. Are phosphodiesterase 4 inhibitors just more theophylline?
Boswell-Smith V; Cazzola M; Page CP
J Allergy Clin Immunol; 2006 Jun; 117(6):1237-43. PubMed ID: 16750981
[TBL] [Abstract][Full Text] [Related]
11. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
Karish SB; Gagnon JM
Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669
[TBL] [Abstract][Full Text] [Related]
12. Agents against cytokine synthesis or receptors.
Yamagata T; Ichinose M
Eur J Pharmacol; 2006 Mar; 533(1-3):289-301. PubMed ID: 16457805
[TBL] [Abstract][Full Text] [Related]
13. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.
Sanz MJ; Cortijo J; Morcillo EJ
Pharmacol Ther; 2005 Jun; 106(3):269-97. PubMed ID: 15922015
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.
Spina D
Drugs; 2003; 63(23):2575-94. PubMed ID: 14636078
[TBL] [Abstract][Full Text] [Related]
15. The role of theophylline and phosphodiesterase4 isoenzyme inhibitors as anti-inflammatory drugs.
Spina D; Landells LJ; Page CP
Clin Exp Allergy; 1998 Aug; 28 Suppl 3():24-34. PubMed ID: 9756183
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase inhibitors.
Boswell-Smith V; Spina D; Page CP
Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S252-7. PubMed ID: 16402111
[TBL] [Abstract][Full Text] [Related]
18. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.
Chapman RW; House A; Jones H; Richard J; Celly C; Prelusky D; Ting P; Hunter JC; Lamca J; Phillips JE
Eur J Pharmacol; 2007 Oct; 571(2-3):215-21. PubMed ID: 17610865
[TBL] [Abstract][Full Text] [Related]
19. 8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
Buckley GM; Cooper N; Dyke HJ; Galleway FP; Gowers L; Haughan AF; Kendall HJ; Lowe C; Maxey R; Montana JG; Naylor R; Oxford J; Peake JC; Picken CL; Runcie KA; Sabin V; Sharpe A; Warneck JB
Bioorg Med Chem Lett; 2002 Jun; 12(12):1613-5. PubMed ID: 12039574
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of phosphodiesterase activity, airway inflammation and hyperresponsiveness by PDE4 inhibitor and glucocorticoid in a murine model of allergic asthma.
Sun JG; Deng YM; Wu X; Tang HF; Deng JF; Chen JQ; Yang SY; Xie QM
Life Sci; 2006 Oct; 79(22):2077-85. PubMed ID: 16875702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
